A vial of the Oxford-AstraZeneca COVID-19 vaccine is seen at Basingstoke Fire Station, in Basingstoke, Britain. (REUTERS)
A vial of the Oxford-AstraZeneca COVID-19 vaccine is seen at Basingstoke Fire Station, in Basingstoke, Britain. (REUTERS)

Three month gap between Oxford vaccine jabs provides better efficacy: Study

The results of the analysis from a phase 3 randomised controlled trial, published in The Lancet journal, suggest that the interval between doses can be safely extended to three months given the protection a single dose offers.
PTI, New Delhi
PUBLISHED ON FEB 20, 2021 12:47 PM IST

A three-month interval between doses of the Oxford Covid-19 vaccine results in higher vaccine efficacy than a six-week gap, according to a new study which says the first dose can offer up to 76 per cent protection in the months between the two jabs.

The results of the analysis from a phase 3 randomised controlled trial, published in The Lancet journal, suggest that the interval between doses can be safely extended to three months given the protection a single dose offers.

According to the researchers, including those from the University of Oxford in the UK, this dosage regimen is beneficial while vaccine supplies are initially limited, and may allow countries to immunize a larger proportion of the population more rapidly.

"Vaccine supply is likely to be limited, at least in the short term, and so policy-makers must decide how best to deliver doses to achieve the greatest public health benefit," said study lead author Professor Andrew Pollard from the University of Oxford.

Pollard believes policies of initially vaccinating more people with a single dose may provide greater immediate population protection than immunising half the number of people with two doses, especially in places where the Oxford vaccine is in limited supply.

"In the long term, a second dose should ensure long-lived immunity, and so we encourage everyone who has had their first vaccine to ensure they receive both doses," he added.

From the study, the researchers sought to understand the effect of different intervals on protection after the second dose, and the risk of infection between jabs -- either due to lower efficacy of a single dose, or rapid waning of efficacy while waiting for the second dose.

They combined data from clinical trials in the UK, Brazil, and South Africa, which together included a total of 17,178 adult participants.

According to the researchers, these participants either received two standard doses of the Oxford Covid-19 vaccine, or a control vaccine/saline placebo.

In the UK trial, they said a subset of participants received a lower dose of the vaccine as their first dose.

The scientists compared the number of symptomatic Covid-19 cases in the control and Covid-19 vaccine groups, occurring more than 14 days after the second dose.

They also estimated the impact of one or two doses of the vaccine on reducing Covid-19 cases as an indicator of how the vaccine might help to reduce transmission in the community.

To evaluate the efficacy of a single dose, the authors assessed participants who had taken their first standard dose but tested positive for Covid-19 more than 21 days afterwards.

According to the scientists, participants who were given their doses 12 or more weeks apart had greater protection than people given their two doses less than six weeks apart.

They said the efficacy results were supported by immune response results in the participants, which found that binding antibody responses were more than two-fold higher in the group having their two vaccines with a longer delay.

After receiving a single standard dose, the researchers said the vaccine efficacy in the participants from 22 days to three months after the immunisation was 76 per cent.

Modelling analysis indicated that this protection did not reduce over the three months, they added.

According to the study, the antibody levels against the SARS-CoV-2 spike protein remained at similar levels for three months.

However, the scientists said it is not yet clear how long protection with a single dose of the vaccine might last, since the trial results are limited to the three months.

So they still recommend a second dose of the vaccine.

"This latest analysis confirms our previous findings of the higher efficacy of a low- then standard-dose regimen," said study co-author Merryn Voyse from the University of Oxford.

"However, with additional data available, we have found that the enhanced efficacy and immunity may be partly driven by the longer interval between doses that was common in this trial group," Voyse said.

She believes the findings further support the relationship between vaccine interval and efficacy in those receiving two standard doses.

According to Voyse, this is the preferred regimen since there are more data to support its use, "and because it is simpler to deliver a vaccine programme when the same vaccine is given for both doses."

SHARE THIS ARTICLE ON
Close
The researchers at the Georgia Institute of Technology and Emory University, US, used the technology to code for a protein called Cas13a that destroys parts of the RNA genetic code which viruses use to replicate in cells in the lungs.(HT Archive/For Representative Purposes Only)
The researchers at the Georgia Institute of Technology and Emory University, US, used the technology to code for a protein called Cas13a that destroys parts of the RNA genetic code which viruses use to replicate in cells in the lungs.(HT Archive/For Representative Purposes Only)

Treatment based on CRISPR can stop replication of Covid-19, flu viruses: Study

PTI, Washington
PUBLISHED ON MAR 05, 2021 04:34 PM IST
The therapy, described in the journal Nature Biotechnology, is based on CRISPR technology, which is normally used to target and edit specific portions of the genetic code -- the way that the four bases of DNA -- A, C, G and T -- are strung together.
Close
The study is the world's largest trial of treatments for hospitalised Covid-19 adults.(Reuters file photo. Representative image)
The study is the world's largest trial of treatments for hospitalised Covid-19 adults.(Reuters file photo. Representative image)

UK Covid-19 trial finds no benefit of gout drug in hospitalised adults

Posted by Harshit Sabarwal | Reuters
PUBLISHED ON MAR 05, 2021 04:06 PM IST
An independent panel suggested pausing recruitment of volunteers in the colchicine arm of the trial based on a preliminary analysis, scientists involved in UK's RECOVERY study said.
Close
The researchers said there is wide variation in how much antibody a person produces in response to vaccination or natural infection.(AP)
The researchers said there is wide variation in how much antibody a person produces in response to vaccination or natural infection.(AP)

Covid-19 antibodies, vaccines less effective against virus variants: Study

Posted by Harshit Sabarwal | PTI, Washington
PUBLISHED ON MAR 05, 2021 02:33 PM IST
The research, published in the journal Nature Medicine, noted that the three fast-spreading variants of the coronavirus first reported in South Africa, the UK and Brazil, can evade antibodies that work against the original form of the virus that sparked the pandemic.
Close
India’s vaccination drive has completed 17,711,287 jabs as of 7pm on Thursday.(HT Photo)
India’s vaccination drive has completed 17,711,287 jabs as of 7pm on Thursday.(HT Photo)

More than 1 million Covid-19 vaccine doses given in a day: Government

By hindustantimes.com | Written by Srivatsan K C, New Delhi
PUBLISHED ON MAR 04, 2021 11:16 PM IST
“Total 10,93,954 vaccine doses were given till 7 pm today, the forty-eighth day of nationwide COVID19 vaccination,” the health ministry said in a statement.
Close
South Africa regulator at 'advanced' stage of Pfizer's Covid-19 vaccine review (Reuters)
South Africa regulator at 'advanced' stage of Pfizer's Covid-19 vaccine review (Reuters)

South Africa regulator at 'advanced' stage of Pfizer Covid-19 vaccine review

Reuters
PUBLISHED ON MAR 04, 2021 10:46 PM IST
According to the South African Health Products Regulatory Authority (SAHPRA), Pfizer's Section 21 application is in advanced stages of review. Such an application, normally valid for six months, is an instrument for emergency use access of a health product that is unregistered.
Close
The isolates or viral samples were recovered from nasal secretions of consenting Covid-19 positive individuals.(Pixabay | Representational image)
The isolates or viral samples were recovered from nasal secretions of consenting Covid-19 positive individuals.(Pixabay | Representational image)

Indian study finds multiple mutations, unique proteins in coronavirus

PTI, Bengaluru
PUBLISHED ON MAR 04, 2021 04:36 PM IST
The study has also shown that the host produces several proteins of their own as their body launches an immunological defence in response to the viral attack.
Close
Canadian company Resverlogix has used the QIMR Berghofer research findings as the basis for expanding its clinical trial of the drug, apabetalone.(Representative image/Bloomberg)
Canadian company Resverlogix has used the QIMR Berghofer research findings as the basis for expanding its clinical trial of the drug, apabetalone.(Representative image/Bloomberg)

Researchers identify cause, potential treatment for Covid-induced heart damage

ANI, Washington
PUBLISHED ON MAR 04, 2021 05:09 AM IST
In severe cases of Covid-19, the immune system overreacts to the infection, releasing inflammatory molecules called cytokines into the bloodstream.
Close
Terezinha da Conceicao, 80, left, and Dulcinea da Silva Lopes, 59, get vaccinated in front of the Christ the Redeemer statue in Rio de Janeiro, Brazil. Data in recent weeks on new variants from South Africa and Brazil has undercut optimism sparked late last year by two vaccines with around 95% efficacy against Covid-19. (AP Photo)
Terezinha da Conceicao, 80, left, and Dulcinea da Silva Lopes, 59, get vaccinated in front of the Christ the Redeemer statue in Rio de Janeiro, Brazil. Data in recent weeks on new variants from South Africa and Brazil has undercut optimism sparked late last year by two vaccines with around 95% efficacy against Covid-19. (AP Photo)

Mutating Covid-19 mars optimism initially brought on by vaccines: Report

Reuters, Chicago
PUBLISHED ON MAR 03, 2021 11:12 PM IST
A new consensus is emerging among scientists, according to Reuters interviews with 18 specialists who closely track the pandemic or are working to curb its impact.
Close
PM Modi, President Kovind, Vice President Naidu, Union minister Harsh Vardhan and eminent Sarod player Ustad Amjad Ali Khan received their first does of Covid-19 vaccine. (HT Photos/Twitter/BeFunkyCollage)
PM Modi, President Kovind, Vice President Naidu, Union minister Harsh Vardhan and eminent Sarod player Ustad Amjad Ali Khan received their first does of Covid-19 vaccine. (HT Photos/Twitter/BeFunkyCollage)

Covid-19 vaccination drive: List of eminent personalities inoculated

By hindustantimes.com | Edited by Shankhyaneel Sarkar, Hindustan Times, New Delhi
UPDATED ON MAR 03, 2021 08:10 PM IST
  • These lawmakers are trying to address vaccine hesitancy which medical experts and lawmakers believe may impact the vaccination drive.
Close
Representational image. (Pratham Gokhale/HT Photo)
Representational image. (Pratham Gokhale/HT Photo)

Covaxin shows 81% efficacy in phase 3 clinical trial: Bharat Biotech

UPDATED ON MAR 04, 2021 03:44 AM IST
The vaccine is stable at 2°C to 8°C (refrigeration) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels
Close
A health worker holding up a Covaxin Covid-19 vaccine vial at Delhi Heart and Lung Institute in New Delhi. (Amal KS/ Hindustan Times)
A health worker holding up a Covaxin Covid-19 vaccine vial at Delhi Heart and Lung Institute in New Delhi. (Amal KS/ Hindustan Times)

Bharat Biotech releases Phase 3 results, says Covaxin has 81% efficacy rate

By hindustantimes.com | Edited by Shankhyaneel Sarkar, Hindustan Times, New Delhi
UPDATED ON MAR 03, 2021 07:53 PM IST
  • Interim clinical efficacy of India-made Covaxin is 81%, says Bharat Biotech
Close
Colorized scanning electron micrograph of an apoptotic cell (greenish brown) heavily infected with SARS-COV-2 virus particles (pink), also known as novel coronavirus, isolated from a patient sample.(Reuters)
Colorized scanning electron micrograph of an apoptotic cell (greenish brown) heavily infected with SARS-COV-2 virus particles (pink), also known as novel coronavirus, isolated from a patient sample.(Reuters)

Study shows how Covid-19 can impact functioning of heart muscles

PTI, Washington
UPDATED ON MAR 03, 2021 02:32 PM IST
The researchers found that viral infection not only kills heart muscle cells but destroys the muscle fibre units responsible for heart muscle contraction.
Close
Pfizer, Oxford vaccines reduce severe Covid-19 in elderly, study finds (REUTERS)
Pfizer, Oxford vaccines reduce severe Covid-19 in elderly, study finds (REUTERS)

Pfizer, Oxford vaccines reduce severe Covid-19 in elderly, study finds

PTI
PUBLISHED ON MAR 02, 2021 06:46 PM IST
A research has found that the respective vaccines developed by Pfizer, and Oxford University-AstraZeneca are highly effective in reducing severe coronavirus infection among people aged 70 years and above.
Close
Health secretary Rajesh Bhushan confirmed that the first dose of the vaccine has been administered to 6,704,856 healthcare workers and a second dose has been administered to 2,598,192 of them.(ANI)
Health secretary Rajesh Bhushan confirmed that the first dose of the vaccine has been administered to 6,704,856 healthcare workers and a second dose has been administered to 2,598,192 of them.(ANI)

Over 14 million Covid-19 vaccine doses administered in India: Government

By hindustantimes.com | Written by Srivatsan K C, New Delhi
PUBLISHED ON MAR 02, 2021 06:44 PM IST
“2.08 lakh doses have been given to people who are 45 years to 59 years of age with comorbidities and people above 60 years of age,” Union health secretary Rajesh Bhushan said.
Close
India-made vaccines suit the needs of developing nations because of its cost-effectiveness and ease of use, experts say.(AP)
India-made vaccines suit the needs of developing nations because of its cost-effectiveness and ease of use, experts say.(AP)

‘Pharmacy of the world’ flexes its vaccine manufacturing muscle

By Rhythma Kaul, New Delhi
PUBLISHED ON MAR 02, 2021 05:54 AM IST
Covishield was developed by Oxford University and drug firm AstraZeneca, and locally manufactured by SII. A million doses of Covishield were shipped to Africa last week under the Covid-19 Vaccines Global Access, or Covax facility — created to ensure global equity in Covid-19 vaccines.
Close
SHARE
Story Saved
OPEN APP